Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q4 FY2021 Earnings Presentation
38 slides from Syngene International's earnings presentation, Apr 27, 2021
Slide 1: Regulation 30 cover letter to stock exchanges
Ref: Syn/CS/SE/BM/2021-22/Apr/16 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com April 27, 2021 To,
Slide 2: Investor Presentation April 2021
Investor Presentation April 2021 Strictly confidential and privileged
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 5: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 6: Q4 growth driven by steady performance in Discovery, Manufacturing and Dedicated Centers
Q4 growth driven by steady performance in Discovery Services, Manufacturing Services and Dedicated Centers. Full year performance consistent with guidance Operating Highlights Financial Highlights: Q4FY21 • Extended strategic collaboration with Bristol Myers Squibb Revenue from Operations^ EBITDA un
Slide 7: Update on COVID-19
Update on COVID-19 Contributing through science Priorities: employee safety & business continuity • Developed effective reagents for use in diagnostic kits to fight the coronavirus, including development of high- Safety and wellbeing Client projects quality, mammalian-derived viral proteins of our p
Slide 8: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 9: Putting science to work: Who we are and what we do
Putting science to work Who we are and what we do ▪ Offering integrated research, development and manufacturing services to take projects from early discovery to commercial supply ▪ Working with clients from around the world to find solutions to their scientific challenges for small and large molecu
Slide 10: Syngene key facts and figures
Syngene key facts and figures All figures are as on March 31, 2021, unless otherwise specified 400+ active clients 8 collaborations 400+ Patents with top 10 pharmaceutical held with clients companies 2 Mn sq. ft. 4700+ talented team of 90% employees of World class infrastructure, scientists in 25-40
Slide 11: The Syngene advantage
The Syngene advantage Integrated service provider offering end-to-end Flexible and varied business models drug discovery, development and manufacturing To cater to client requirement services on a single platform International accreditations Experienced in successfully managing large OHSAS 18001, GL
Slide 12: Our experience spans multiple industry segments and global partnerships
Our experience spans multiple industry segments and partnerships with global leaders across the world Clinical-stage company Leading manufacturer creating novel medicines of high-tech polymer targeting materials G protein-coupled receptors (GPCRs) Germany head Leading China based crop quartered chem
Slide 13: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 14: Biocon group and Syngene
Biocon group and Syngene • Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company • Syngene, a subsidiary of Biocon Limited, was established in 1993 as India’s first Contract Research Organization - Company has 25 years plus of unparalleled experience in novel molecu
Slide 15: About us
About us All figures in Rs. Mn unless otherwise specified A Global CRO Quality Focus • Integrated Drug Discovery, Development and • Quality driven organization Manufacturing service provider • Excellent track record of compliance with • Small and Large Molecules, ADCs, global regulators Oligonucleot
Slide 16: Our journey so far
Our journey so far All figures in Rs. Mn unless otherwise specified Foundation Globalization and strategic acquisition • Operations started • Expanded into formulations development • Expansion of R&D Lab • Contract with Endo Pharmaceuticals to develop novel anti cancer biological • Granted 100% Expo
Slide 17: Strong track record of growth and profitability
Strong track record of growth and profitability All figures in Rs. Mn unless otherwise specified ▪ Growth driven by increase in sales from existing clients and acquisition of new clients Client Base Client Footprint (%) ▪ “Engage, expand and extend” strategy to extend client relationship over a long
Slide 18: Multiple levers for growth going ahead
Multiple levers for growth going ahead Expand/Extend Existing Clients Capacity Expansion - High service integration - Consistent investment - Dedicated centers model - FTE services, manufacturing, formulation, biologics, stability Engage New Clients - Tailored service offerings and Client Capacity d
Slide 19: Our divisions
Our divisions Discovery Development Manufacturing Dedicated Services Services Services R&D Centers Solution: Conducts early-stage Solution: Encompasses activities Solution: Manufacturing services for Solution: These centers offer research, from target identification from pre-clinical to clinical tri
Slide 20: Our collaboration models
Our collaboration models Dedicated R&D Labs FTE FFS Risk-reward • Dedicated scientific resources • Dedicated scientific and support • Flexible, on-demand resources with • Rewards based on clearly defined, selected from partner-specified personnel customized and managed to targeted skill sets pre-agr
Slide 21: Our dedicated R&D centers are an industry leading model
Our dedicated R&D centers are an industry leading model >600 Scientists c.200 Scientists c.170 Scientists 8 Scientists 300,000+ sq. ft. laboratory space 70,000 sq. ft. laboratory space 60,000 sq. ft. laboratory space 3,200 sq. ft. laboratory space Largest R&D Center in Asia for BMS Dedicated R&D Cen
Slide 22: Our end-to-end platform: one-stop-shop for discovery, development and manufacturing
Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules) Discovery Development Manufacturing Chemistry Drug Substance Clinical Supplies Drug Product Small Molecules Large Biology Molecules Integrated Drug Substance – HPAPI Dr
Slide 23: Discovery Services: From target to a drug candidate
Discovery Services: From target to a drug candidate Candidate Hit to lead Lead optimisation Development selection Candidate Candidate 5 Lead Selection Development Compounds Exploratory PK, Tox and Developability Assessment 20 Lead In-Vivo DMPK Profiling, Compounds CADD 500 Lead Generation of focused
Slide 24: Development Services
Development Services ▪ Encompass activities across multiple disciplines as a molecule moves from pre- clinical to clinical trials Preclinical Studies ▪ Key activities include: Drug product ▪ Drug substance development (process R&D and optimisation) Drug Dvpt. Substance ▪ Drug product development (pr
Slide 25: Manufacturing Services
Manufacturing Services Small Molecules • State-of-the-art cGMP (Current Good Manufacturing Practices) and GMP(Good Manufacturing Practice) facility to manufacture new chemical entities (NCEs) • Designed to support multi gram to 100s of kgs/ batch of Intermediates and APIs for clinical trials • New g
Slide 26: Backed by world class state of the art infrastructure
Backed by world class state of the art infrastructure HQ Campus – 90 Acres in Bangalore where most of Syngene’s capabilities are R&D Expansion: Genome housed today Valley, Hyderabad, India commenced operation in Aug 2019 Biologics Expansion: HQ Campus Biologics Manufacturing Plant API Mfg Expansion:
Slide 27: Supported by our highly experienced and qualified team of scientists
Supported by our highly experienced and qualified team of scientists ~5,400* ~70,000 25*% strong pool of employees hours of training per year female employees vs 15% in FY16 Environment that engages our employees and enables them to grow 4700+ scientists delivering quality Promoting cross-functional
Slide 28: Led by a globally experienced management team
Led by a globally experienced management team Management team Jonathan Hunt Managing Director and Dr. Mahesh Bhalgat Sibaji Biswas Ashu Tandon Vinita Shrivastava Chief Executive officer Chief Operating Officer Chief Financial Officer Chief Commercial Officer Chief Human Resources Officer Previous As
Slide 29: Advised by visionary Board of Directors
Advised by visionary Board of Directors Member of he Board Vinita Bali Kiran Mazumdar Shaw Jonathan Hunt Dr. Carl Dcicco Professor Catherine Rosenberg Non-Executive Chairperson Managing Director and Chief Independent Director Non-Executive Director Independent Director Executive officer Chairperson
Slide 30: Committed to sustainability
Committed to sustainability Safety is at the heart of everything we do Committed to environmental protection Accredited with ISO 14001:2015 for its effective Accredited with ISO 45001:2018 for its Occupational Health Environment Management System (EMS) and Safety (OH&S) measures of water conserved t
Slide 31: Industry recognition for scientific capability and best practices
We have consistently received industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018 - At Bengaluru • CMO Leadership Award Winner 2020 - under • Dynamic Enterprise of the Year 2016 - Tech Summit, Bengaluru Categories: Capabilities, Compatibility, At the 9th
Slide 32: Proactively managing risks
Proactively managing risks Mitigation Risk Mitigation • Widening scope of engagement • BCP in place to ensure continuity of through new service offerings Client retention and operations (Technology to aid remote • Investment in business development growth working, Continuous vendor engagement to Bus
Slide 33: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 34: Q4FY21 financials
Q4FY21 financials All figures in Rs. Mn unless otherwise specified Particulars Q4 FY21 Q4 FY20 YoY Change Q3 FY21 QoQ change Revenue from operations 6,586 5,843 13% 5,839 13% (excluding export incentives) Export incentives - 230 6 Other Income 184 205 (10%) 171 8% Total Revenue 6,770 6,278 8% 6,016
Slide 35: FY21 financial highlights
FY21 financial highlights All figures in Rs. Mn unless otherwise specified Particulars FY21 FY20 YoY Change Revenue from operations (excl export incentives) 21,802 19,465 12% Balance Sheet Highlights Export incentives 41 654 (94%) Other Income 646 816 (21%) Total Revenue 22,489 20,935 7% As on 31st
Slide 36: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 37: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* NSE Ticker SYNGENE BSE Ticker 539268 1% Promoter & Market Cap (Rs. Mn) 2,17,380 29% Promoter Group % free-float 28.7% Public Free-float market cap (Rs. Mn) 62,410 Share Outstanding (Mn) 400 ESOP Trust 3M
Slide 38: Thank you
THANK YOU For more details www.syngeneintl.com • Visit www.syngeneintl.com • IR Contact: Krishnan G + 91 806 891 9807 investor@syngeneintl.com Putting Science to Work
Syngene International — Q4 FY2021 Earnings Presentation on 6ix